ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,784.80
0.20%
S&P ASX All Technology
3,090.70
0.65%
Brent Oil
84.94
-0.08%
US Dollar vs AUD
1.49993
-0.07%
Bitcoin
64,610.68
-0.32%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX

  6. Palatin Technologies Inc New (PTN) Share Price

Palatin Technologies Inc New

Palatin Technologies Inc New (PTN)

Palatin Technologies Inc
Proton Capital Corp
1.88
-0.19
(-9.18%)
Closed 21 June 6:00AM
Delayed by 15 minutes
1.95
0.07
(3.72%)
After Hours: 9:25AM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
1.95
Bid
-
Offer
-
Volume
126,487
1.86 Day's Range 2.0944
1.43 52 Week Range 5.65
Market Cap
30.337M
Previous Close
2.07
Open
2.08
Last Trade
425
@
1.88
Last Trade Time
Financial Volume
US$ 249,066
VWAP
1.9691
Average Volume (3m)
402,892
Shares Outstanding
16,136,640
Dividend Yield
-
PE Ratio
-1.10
Earnings Per Share (EPS)
-1.71
Revenue
5.88M
Net Profit
-27.54M

About Palatin Technologies Inc New

Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the me... Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
palatin.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Palatin Technologies Inc New is listed in the Pharmaceutical Preparations sector of the American Stock Exchange with ticker PTN. The last closing price for Palatin Technologies was US$2.07. Over the last year, Palatin Technologies shares have traded in a share price range of US$ 1.43 to US$ 5.65.

Palatin Technologies currently has 16,136,640 shares in issue. The market capitalisation of Palatin Technologies is US$30.34 million. Palatin Technologies has a price to earnings ratio (PE ratio) of -1.10.

PTN Latest News

More News

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) PR Newswire CRANBURY, N.J., June 20, 2024...

18 hours ago
PR Newswire (US)

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity PR Newswire CRANBURY, N.J., June 12, 2024 Co-Administration Phase 2 study of bremelanotide with tirzepatide...

12 June 2024
PR Newswire (US)

Form 8-K - Current report

15 May 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

15 May 2024
Edgar (US Regulatory)

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire CRANBURY, N.J., May 15, 2024 Positive Phase 3 PL9643 MELODY-1 Pivotal Study...

15 May 2024
PR Newswire (US)

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 PR Newswire CRANBURY, N.J., May 9, 2024 CRANBURY, N.J., May 9, 2024 /PRNewswire/...

09 May 2024
PR Newswire (US)

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity PR Newswire CRANBURY, N.J., May 2, 2024 Phase 2...

02 May 2024
PR Newswire (US)

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 PR...

30 April 2024
PR Newswire (US)
Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.02-1.01522842641.972.09441.741085611.94806189CS
4-0.1-4.878048780492.052.131.74938901.93663427CS
120.3421.11801242241.612.881.614028922.00671853CS
26-0.35-15.21739130432.35.651.464815752.69044278CS
52-0.29-12.94642857142.245.651.432934082.59695692CS
1561.37236.2068965520.588.60.181112008110.79752663CS
2600.6145.52238805971.348.60.181117367210.78215785CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
K2FK2fly Limited
AUD 0.1825
(82.50%)
2.06M
ME1OEMelodiol Global Health Ltd
AUD 0.005
(66.67%)
25
MTBMount Burgess Mining Nl
AUD 0.0015
(50.00%)
5.38k
ARVOCArtemis Resources Limited
AUD 0.003
(50.00%)
1.05M
TSLTitanium Sands Limited
AUD 0.007
(40.00%)
967.96k
FRSOAForrestania Resources Ltd
AUD 0.006
(-57.14%)
26k
GGEOAGrand Gulf Energy Limited
AUD 0.001
(-50.00%)
2.18M
D2OOADuxton Water Limited
AUD 0.021
(-47.50%)
4.5k
SGCSacgasco Limited
AUD 0.003
(-40.00%)
196.7k
CT1Constellation Technologies Limited
AUD 0.002
(-33.33%)
50.02k
JRVJervois Global Ltd
AUD 0.022
(22.22%)
34.81M
BOTBotanix Pharmaceuticals Limited
AUD 0.352
(5.07%)
33.87M
CCOCalmer Co International Ltd
AUD 0.007
(-12.50%)
24.73M
PLSPilbara Minerals Limited
AUD 3.085
(-3.44%)
21.01M
REDRed 5 Limited
AUD 0.4175
(3.09%)
19.99M

PTN Discussion

View Posts
mike1986 mike1986 2 months ago
You may just get your wish. This stock has been making promises for years and now expects everyone to wait until 2025 for any hope of marketing its dry eye ointment, while looking for a partner to do the heavy lifting. Ahhhhhhh..........
👍️0
Stockexpertpro Stockexpertpro 2 months ago
PTN Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

https://finance.yahoo.com/news/palatin-announces-phase-3-pl9643-113000533.html
👍️0
zeusgodmd zeusgodmd 3 months ago
Waiting for 1.25
👍️0
Monksdream Monksdream 3 months ago
PTN under $2
👍️0
mte1955 mte1955 4 months ago
Well just great. Pump it the few days before the announcement and sell it on the news.
👍️0
mike1986 mike1986 4 months ago
I love the way these low cap stocks move up and down on no news.
👍️0
mike1986 mike1986 4 months ago
On the move with high volume. Hope something announced soon.
👍️ 1
mte1955 mte1955 4 months ago
So I guess people are disappointed with the latest report. Nothing new but nothing detrimental either.
👍️0
zeusgodmd zeusgodmd 5 months ago
Did not see that coming. Why can’t they what. Til after the news
👍️0
zeusgodmd zeusgodmd 5 months ago
Guess no news this week
👍️0
zeusgodmd zeusgodmd 6 months ago
There are people here that seem to start buying 3 days before a big announcement but everybody is looking at before the end of the year will see
👍️0
power11 power11 6 months ago
ANY SPECIFIC DATE ???
THANKS
👍️0
zeusgodmd zeusgodmd 6 months ago
News next week
👍️0
zeusgodmd zeusgodmd 7 months ago
Good luck in am. Need a new partner to launch eye sauce. Royalty payments with a down payment. New sex med, new Ibs med why are we at 2$
👍️0
zeusgodmd zeusgodmd 8 months ago
It was going a nice direction why fk it up.
👍️0
mike1986 mike1986 8 months ago
Seems more like unloading today. Buy the rumor, sell the news.
👍️0
zeusgodmd zeusgodmd 8 months ago
Highest volume in over a year will take it. Money managers starting the load
👍️0
zeusgodmd zeusgodmd 8 months ago
Stepping up the right way
👍️0
zeusgodmd zeusgodmd 8 months ago
It’s only up one buck a lot more money to be made
👍️0
johnb214 johnb214 8 months ago
All time is around 1,670.00. A large Pharma should buy the stock and acquire it versus just paying for one or two of their drugs.
👍️0
zeusgodmd zeusgodmd 8 months ago
Nice moves not 8 yet
👍️0
zeusgodmd zeusgodmd 8 months ago
Last 3 days tells the story people loading the boat
👍️0
zeusgodmd zeusgodmd 8 months ago
Hw investors calling for 75$ I’ve seen that call once by them at it was right on rambus stock
👍️0
zeusgodmd zeusgodmd 8 months ago
Not to 8$ yet
👍️0
zeusgodmd zeusgodmd 8 months ago
Will take shorts 5 days to cover. Good run
👍️0
zeusgodmd zeusgodmd 8 months ago
Stock going to get out of the shitter soon should be 8$
👍️0
zeusgodmd zeusgodmd 8 months ago
They need to start looking for a marketing and sale partnership for eye product and Ibs product
👍️0
zeusgodmd zeusgodmd 8 months ago
Good loading day. Good news will come.
👍️0
zeusgodmd zeusgodmd 8 months ago
Maybe falls to floor tomorrow time to buy good luck to sll
👍️0
zeusgodmd zeusgodmd 8 months ago
It time for them to get in bed with a eye company and get some funding and royalty plans with them.
👍️ 1
Monksdream Monksdream 9 months ago
PTN under $2
👍️0
zeusgodmd zeusgodmd 10 months ago
Let’s see 2.00
👍️0
zeusgodmd zeusgodmd 10 months ago
Will see 220 soon
👍️0
mike1986 mike1986 10 months ago
Buy on the rumor, sell on the news!
👍️0
mike1986 mike1986 10 months ago
Nice move last few day. Congratulations to the faithful!
👍️0
zeusgodmd zeusgodmd 11 months ago
Bad new coming I quess
👍️0
AJ Freely AJ Freely 11 months ago
$PTN - Up 8% Pre-Market/ Current Price $2.44
Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi® Product Revenue Results
??31% growth over 2Q '23; 165% growth over 3Q '22
👍️0
zeusgodmd zeusgodmd 11 months ago
Nice day something up
👍️0
zeusgodmd zeusgodmd 12 months ago
Yes there’s only like 11 million shares to this company and maybe 8 million warrants at higher prices. They have 3 good pipeline s of new drugs. First one will shoot it to 30 once nda gets approval. This one should be 8$ already with the low float. It will be bought and taken out buy a big eye company and the ulcerative colitis will be bought or co sold with Merck or another big boy wait and see
👍️0
stevenjklein stevenjklein 12 months ago
PTN Palatin Technologies, Inc.

Stock Split History (link goes to Seeking Alpha)

Date Ratio
Aug. 31, 2022 1:25
Sep. 27, 2010 1:10
Sep. 08, 1997 1:4
Jul. 22, 1996 1:10
👍️0
zeusgodmd zeusgodmd 12 months ago
The board has to get there shares before the company gets sold. Now set the price
👍️0
zeusgodmd zeusgodmd 1 year ago
I think we will see in next year no problem when products go to nda they will be bought buy a big guy or partners with ability to buy Ibs drug also that is where the stock will shoot the gap
👍️0
mike1986 mike1986 1 year ago
Well at $8 I am ahead. $ 20 makes this a home run.
👍️0
zeusgodmd zeusgodmd 1 year ago
They also did a 20 for one stock split to shares trading at 10 cents it will go up fast with good news. Should be 8$ by now
👍️0
zeusgodmd zeusgodmd 1 year ago
Company’s future and products. If they start selling sex drug Europe then profits going up. But there pipeline is in stage 2 and 3 drugs with eye drug will be a good deal with all the old people in the USA. Those drugs are expensive any eye drops. They will partner up with some big company for there sales force and probably get a payment up front and royalties then the Ibs drug comes out of the pipe game on. HW a research company has company valued at 75$ a share.
👍️0
mike1986 mike1986 1 year ago
You have any idea why the stock has been strong the past two days. I saw nothing in the quarterly report that was dramatic but maybe I missed something.
👍️0
zeusgodmd zeusgodmd 1 year ago
We need a company to join and help market eye drops and we go up.
👍️0
zeusgodmd zeusgodmd 1 year ago
New after hours didn’t know they where starting to ramp up sex drug sales overseas but 2 companies going for it.
👍️0
zeusgodmd zeusgodmd 1 year ago
Shares tight here. Seems to be going up
👍️0
zeusgodmd zeusgodmd 1 year ago
HW says worth 75$ let start with 20$ a share
👍️0

Your Recent History

AMEX
PTN
Palatin Technologies
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved